Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine plus escitalopram rapid antidepressant mechanistic study in major depressive disorder
ChiCTR2600120947Phase 4Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Study group: memantine + escitalopram, Control group: escitalopram + memantine placebo and Pre-test group: memantine monotherapy (3 arms). Primary endpoint: Change in MADRS score from baseline at end of week 1. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
memantineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600120947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120947.